Video

Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency

Author(s):

Saro Arakelians, PharmD

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:

  • For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
  • Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
  • Chronic immune thrombocytopenia (ITP) in adults.

Related Videos
Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule - Image credit: vchalup | stock.adobe.com
Pharmacist and patient in a community pharmacy -- Image credit: Gorodenkoff | stock.adobe.com
X-ray image of human brain with neurons -- Image credit: Who is Danny | stock.adobe.com
Related Content
Syringe and vial labeled GLP 1 are prominently displayed, symbolizing medical advancements and treatments. background features blurred, colorful pattern, enhancing focus on medical items - Image credit: mingnimit | stock.adobe.com
April 9th 2025

Expert Q&A: Exploring the Role of GLP-1 Receptor Agonists in Diabetes Management

Kennedy Ferruggia, Assistant Editor Elaina Rosario, PharmD, CPh, BCACP, CDCES
Everything You Need to Know From the American College of Cardiology 2025 Scientific Session
April 1st 2025

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP Aislinn Antrim, Managing Editor
Child with a migraine -- Image credit: irena_geo | stock.adobe.com
April 8th 2025

AAN 2025: Fremanezumab Superior to Placebo in Reducing Monthly Migraine Days in Children and Adolescents

Gillian McGovern, Associate Editor
Pharmacy focus podcast
March 28th 2025

From Screening to Survival: The Pharmacist’s Role in Colorectal Cancer

Alexandra Gerlach, Associate Editor
fda on paper texture - Image credit: Araki Illustrations | stock.adobe.com
April 8th 2025

Nivolumab Plus Ipilimumab Receives FDA Approval for MSI-H/dMMR mCRC

Kennedy Ferruggia, Assistant Editor
Depiction of brain health -- Image credit: melita | stock.adobe.com
April 8th 2025

AAN 2025: APP Care Models Can Be a Solution to Promoting Patient Access and Equity Within the Neurology Space

Gillian McGovern, Associate Editor